167 related articles for article (PubMed ID: 38642459)
21. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.
Merseburger AS; Bakshi G; Chen DY; Chiong E; Jabbour M; Joung JY; Lai AY; Lawrentschuk N; Le TA; Ng CF; Ng CT; Ong TA; Pang JS; Rabah DM; Ragavan N; Sase K; Suzuki H; Teo MMH; Uemura H; Woo HH
World J Urol; 2024 Mar; 42(1):156. PubMed ID: 38483562
[TBL] [Abstract][Full Text] [Related]
22. A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2).
Crabb S; Morgan A; Hunter MS; Stefanopoulou E; Griffiths G; Richardson A; Fenlon D; Fleure L; Raftery J; Boxall C; Wilding S; Nuttall J; Eminton Z; Tilt E; O'Neill A; Bacon R; Martin J
Trials; 2023 Jul; 24(1):450. PubMed ID: 37430353
[TBL] [Abstract][Full Text] [Related]
23. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
[TBL] [Abstract][Full Text] [Related]
25. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
26. Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer.
Wallis CJD; Satkunasivam R; Herschorn S; Law C; Seth A; Kodama RT; Kulkarni GS; Nam RK
Urol Oncol; 2018 May; 36(5):241.e1-241.e6. PubMed ID: 29503141
[TBL] [Abstract][Full Text] [Related]
27. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
28. Improving bone health in prostate cancer patients starting androgen deprivation therapy: does Fracture Risk Assessment Tool (FRAX®) enhance stratification and targeted management?
Sharqawi A; Hewitt K; Alexander C; El-Sakka AI; Lee L
Arch Osteoporos; 2022 Nov; 17(1):143. PubMed ID: 36376762
[TBL] [Abstract][Full Text] [Related]
29. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
[TBL] [Abstract][Full Text] [Related]
31. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
32. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects.
Corona G; Gacci M; Baldi E; Mancina R; Forti G; Maggi M
J Sex Med; 2012 Mar; 9(3):887-902. PubMed ID: 22248394
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients.
Muniyan S; Xi L; Datta K; Das A; Teply BA; Batra SK; Kukreja RC
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188383. PubMed ID: 32535158
[TBL] [Abstract][Full Text] [Related]
34. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.
Kim DK; Lee HS; Park JY; Kim JW; Ha JS; Kim JH; Yang WJ; Cho KS
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1217-1226. PubMed ID: 33000338
[TBL] [Abstract][Full Text] [Related]
35. Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy.
Pinthus JH; Duivenvoorden WCM; Klotz L; Mukherjee SD; Siemens DR; Niazi T; Fradet V; Foster W; Duceppe E; Taussky D; Hamilton R; Lavallée L; Brown I; Chin J; Gopaul D; Wassef A; Kassouf W; Davis M; Violette PD; Agapay S; Balasubramanian K; Mian R; Rangarajan S; Sener A; Shayegan B; Devereaux PJ; Leong DP
J Urol; 2022 May; 207(5):1020-1028. PubMed ID: 34978211
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines.
Cheung AS; Pattison D; Bretherton I; Hoermann R; Lim Joon D; Ho E; Jenkins T; Hamilton EJ; Bate K; Chan I; Zajac JD; Grossmann M
Andrology; 2013 Jul; 1(4):583-9. PubMed ID: 23686896
[TBL] [Abstract][Full Text] [Related]
37. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison.
Donovan KA; Gonzalez BD; Nelson AM; Fishman MN; Zachariah B; Jacobsen PB
Psychooncology; 2018 Jan; 27(1):316-324. PubMed ID: 28557112
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
Collier A; Ghosh S; McGlynn B; Hollins G
Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
[TBL] [Abstract][Full Text] [Related]
39. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
[TBL] [Abstract][Full Text] [Related]
40. Background to and management of treatment-related bone loss in prostate cancer.
Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L
Drugs Aging; 2002; 19(12):899-910. PubMed ID: 12495366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
